Edesa Biotech, Inc.
EDSA
Positions held
Your positionsEDSA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $49.45M | Enterprise value | $33.37M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 89.27 | Beta | 1.22 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -122.9% | ROA | -66.4% | Debt / equity | — |
| Current ratio | 2.76 | Free cash flow | -$4.01M | Analyst recommendation | none | Mean target | $16.33 |
| 52w high | $20.32 | 52w low | $0.72 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$5.4M | -$4.2M | -$2.2M | -$2.2M | -$1.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$5.4M | -$4.2M | -$2.2M | -$2.2M | -$1.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$7.2M | -$6.2M | -$8.4M | -$17.5M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$7.1M | -$6.3M | -$8.6M | -$17.6M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-28 · 3 Small Cap Biotech Stocks Trading At A Discount With Late Stage Clinical Catalysts
2026-08-24 · EDSA: Recruitment in Phase 2 Vitiligo Study Set to Get Underway
2026-08-20 · Edesa Biotech Stock Sinks After Fresh Capital Raise
2026-08-20 · Edesa Biotech Announces Pricing of $25.0 Million Public Offering
2026-08-19 · Edesa Biotech Launches Public Offering of Common Shares, Warrants
2026-08-19 · Edesa Biotech Announces Proposed Public Offering
2026-08-13 · Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
Price (daily)
Full chart · RSI · MACD · patterns